New in The Innovation Drug Discovery!
Limertinib adopts a combination of mutation selectivity and irreversible inhibition design, which can provide a new option for the treatment of EGFR mutant lung cancer.
doi.org/10.59717/j.x...
#NonSmallCellLungCancer #targetedtheraphy